Supplement researchSourced from PubMed and NIH
NutriStack
Free iPhone appUpdated September 28, 2026

Supplement × Prescription·Evidence index

Fluvoxamine and Melatonin: what the research found

PubMed indexes 8 records that name Fluvoxamine and Melatonin together, either in the title or in an interaction, co-administration, or pharmacokinetic context. The key findings come first, in the authors’ own words, followed by every study with its design and PubMed link.

A summary of published research, not medical advice. A pharmacist can check any combination against your full list of medicines and supplements.

Key findings

What the studies concluded.

Reviews and human studies first. Each quote is the authors’ own conclusion about their study, not a NutriStack assessment, and a single study is not a consensus.

“The administration of fluvoxamine to patients with depressive state after cerebral infarction alleviated both the depressive state and sleep disturbances. Increased melatonin levels by the administration of fluvoxamine may contribute to improvement in sleep disturbance, one of the major symptoms of depression.”

Sunami et al. · 2012 · Human study · details

“The authors concluded that fluvoxamine is a potent inhibitor of melatonin degradation. Because this inhibitory action is also found in vivo, fluvoxamine might be used as an enhancer of melatonin, which might offer new therapeutic possibilities of fluvoxamine.”

Härtter et al. · 2001 · Human study · details

“This study showed an increase in the bioavailability of oral melatonin by coadministration of fluvoxamine. The effects of fluvoxamine on the melatonin serum concentrations in patients with depression might therefore be caused by inhibition of the elimination of melatonin and not attributable to an increased production of melatonin.”

The research

8 studies naming Fluvoxamine and Melatonin.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction.

Internal medicine (Tokyo, Japan) · 2012 · PMID 22687788

Controlled Clinical Trial

“The administration of fluvoxamine to patients with depressive state after cerebral infarction alleviated both the depressive state and sleep disturbances. Increased melatonin levels by the administration of fluvoxamine may contribute to improvement in sleep disturbance, one of the major symptoms of depression.”

Sunami et al. · Authors' conclusion

Names both Fluvoxamine and Melatonin in its title.

Increased bioavailability of oral melatonin after fluvoxamine coadministration.

Clinical pharmacology and therapeutics · 2000 · PMID 10668847

Clinical Trial

“This study showed an increase in the bioavailability of oral melatonin by coadministration of fluvoxamine. The effects of fluvoxamine on the melatonin serum concentrations in patients with depression might therefore be caused by inhibition of the elimination of melatonin and not attributable to an increased production of melatonin.”

Härtter et al. · Authors' conclusion

Names both Fluvoxamine and Melatonin in its title.

Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.

European journal of clinical pharmacology · 2000 · PMID 10877005

Clinical TrialRandomized Controlled Trial

“The serum MT level increased markedly after ingestion of FLU but not after CIT. The exact mechanism behind this finding is unknown, but decreased hepatic metabolism of MT by either CYP1A2 or CYP2C19, or both, is probable. Although exogenous MT, causing high MT concentration in plasma, has sleep-promoting properties in man, it is at this stage unknown whether serum MT concentrations in the range found in this study have similar effects.”

von Bahr et al. · Authors' conclusion

Names both Fluvoxamine and Melatonin in its title.

Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

British journal of clinical pharmacology · 1994 · PMID 8186063

Clinical TrialComparative StudyRandomized Controlled Trial

“7. The drug treatments affected different aspects of the nocturnal plasma melatonin profile suggesting that the amplitude of the melatonin rhythm may depend upon serotonin availability and/or melatonin metabolism whilst the onset of melatonin production depends upon noradrenaline availability.”

Skene et al. · From the abstract

Names both Fluvoxamine and Melatonin in its title.

Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.

Journal of clinical psychopharmacology · 2001 · PMID 11270913

Human subjects

“The authors concluded that fluvoxamine is a potent inhibitor of melatonin degradation. Because this inhibitory action is also found in vivo, fluvoxamine might be used as an enhancer of melatonin, which might offer new therapeutic possibilities of fluvoxamine.”

Härtter et al. · From the abstract

Names both Fluvoxamine and Melatonin in its title.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

How to read this page

A literature summary, not guidance.

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Fluvoxamine, Melatonin, and several hundred other substances.

Log your routine, get reminders at the times you choose, and scan a label to add a product. The checker is a research and organisation tool, not a clinical decision aid.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.